MA41188B1 - Compositions d'insuline à action rapide - Google Patents
Compositions d'insuline à action rapideInfo
- Publication number
- MA41188B1 MA41188B1 MA41188A MA41188A MA41188B1 MA 41188 B1 MA41188 B1 MA 41188B1 MA 41188 A MA41188 A MA 41188A MA 41188 A MA41188 A MA 41188A MA 41188 B1 MA41188 B1 MA 41188B1
- Authority
- MA
- Morocco
- Prior art keywords
- acting insulin
- rapid acting
- chloride
- insulin compositions
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition d'insuline humaine ou d'un analogue de l'insuline qui comprend des concentrations spécifiques de citrate, de chlorure, dans certains cas comprenant l'ajout de chlorure de sodium, de zinc et, facultativement, de chlorure de magnésium et/ou de surfactant, et qui a une action pharmacocinétique et/ou pharmacodynamique plus rapide que les formulations commerciales de produits analogues de l'insuline existants.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462092407P | 2014-12-16 | 2014-12-16 | |
PCT/US2015/064744 WO2016100042A1 (fr) | 2014-12-16 | 2015-12-09 | Compositions d'insuline à action rapide |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41188A MA41188A (fr) | 2017-10-24 |
MA41188B1 true MA41188B1 (fr) | 2022-08-31 |
Family
ID=55066806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41188A MA41188B1 (fr) | 2014-12-16 | 2015-12-09 | Compositions d'insuline à action rapide |
Country Status (17)
Country | Link |
---|---|
US (3) | US9993555B2 (fr) |
EP (2) | EP4108253A1 (fr) |
JP (4) | JP6328855B2 (fr) |
AR (1) | AR102869A1 (fr) |
DK (1) | DK3233108T3 (fr) |
ES (1) | ES2911207T3 (fr) |
HR (1) | HRP20220692T1 (fr) |
HU (1) | HUE058764T2 (fr) |
LT (1) | LT3233108T (fr) |
MA (1) | MA41188B1 (fr) |
MD (1) | MD3233108T2 (fr) |
PL (1) | PL3233108T3 (fr) |
PT (1) | PT3233108T (fr) |
RS (1) | RS63174B1 (fr) |
SI (1) | SI3233108T1 (fr) |
TW (1) | TW201630622A (fr) |
WO (1) | WO2016100042A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2910570B1 (fr) | 2008-03-18 | 2016-10-12 | Novo Nordisk A/S | Analogues de l'insuline acylés, stabilisés à la protéase |
CN104902922B (zh) | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
JP7145849B2 (ja) * | 2016-09-29 | 2022-10-03 | アレコル リミテッド | 新規の製剤 |
SI3554534T1 (sl) | 2016-12-16 | 2021-09-30 | Novo Nordisk A/S | Farmacevtski sestavki, ki vsebujejo inzulin |
US20180236080A1 (en) * | 2017-02-22 | 2018-08-23 | Adocia | Fast-acting insulin composition comprising a citric acid salt |
CN110582264B (zh) * | 2017-03-26 | 2022-11-11 | V·R·斯塔福德 | 眼睑皮肤状况的处理方法 |
JOP20190277B1 (ar) * | 2017-06-01 | 2023-09-17 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
WO2019193349A1 (fr) | 2018-04-04 | 2019-10-10 | Arecor Limited | Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline |
IL277720B2 (en) | 2018-04-04 | 2024-03-01 | Arecor Ltd | A medical infusion pump system for administration of an insulin compound |
EP3773474A1 (fr) | 2018-04-04 | 2021-02-17 | Arecor Limited | Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline |
WO2019243627A1 (fr) | 2018-06-23 | 2019-12-26 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
FR3083985A1 (fr) | 2018-07-23 | 2020-01-24 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
CA3129569A1 (fr) * | 2019-03-14 | 2020-09-17 | Thomas Weimbs | Procedes et compositions pour la prise en charge de la sante renale |
US10639328B1 (en) * | 2019-03-27 | 2020-05-05 | College Of William & Mary | Compositions and methods for reducing hyperglycemia and treating diabetes |
US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
WO2021055505A2 (fr) * | 2019-09-17 | 2021-03-25 | Cass Pharmaceuticals, Inc. | Formulations d'insuline et de glucagon injectables par voie sous-cutanée et procédés d'administration |
CN115176155A (zh) | 2019-10-25 | 2022-10-11 | 塞卡科实验室有限公司 | 指示剂化合物、包括指示剂化合物的装置及其制备和使用方法 |
GB202004814D0 (en) | 2020-04-01 | 2020-05-13 | Arecor Ltd | Novel formulations |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK116527B (da) | 1967-03-01 | 1970-01-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
NO162160C (no) | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
DE10075034I1 (de) | 1987-02-25 | 2001-05-23 | Novo Nordisk As | Insulinderivate |
JPH04502465A (ja) | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
US5716927A (en) | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
AUPO066096A0 (en) | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
JP2002535287A (ja) | 1999-01-26 | 2002-10-22 | イーライ・リリー・アンド・カンパニー | 単分散性6量体のアシル化されたインスリンアナログ製剤 |
WO2001035943A2 (fr) | 1999-11-15 | 2001-05-25 | Gangal Hanamaraddi T | Preparation de fluides a base de dextrose et d'insuline destinee a une infusion intraveineuse |
JP4147234B2 (ja) | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
JP4800959B2 (ja) | 2003-11-13 | 2011-10-26 | ノヴォ ノルディスク アー/エス | 糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物 |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
ES2398318T3 (es) | 2004-03-12 | 2013-03-15 | Biodel, Inc. | Composiciones de suministro de fármacos de acción rápida |
US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US20070086952A1 (en) | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
AU2007238114B2 (en) | 2006-04-12 | 2010-10-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
WO2008013955A2 (fr) | 2006-07-27 | 2008-01-31 | Nektar Therapeutics | Formulations à libération prolongée pour administration pulmonaire |
JP5552046B2 (ja) * | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー/エス | インスリン誘導体を含有する薬学的製剤 |
EP2036539A1 (fr) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Formulations stables d'amyline et ses analogues |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
US20120094902A1 (en) | 2009-03-27 | 2012-04-19 | Adocia | Fast-acting insulin formulation |
FR2943538B1 (fr) | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
PL2612677T3 (pl) | 2009-06-26 | 2015-10-30 | Novo Nordisk As | Preparat zawierający insulinę, nikotynamid i argininę |
CA2805031A1 (fr) | 2010-07-07 | 2012-01-12 | Biodel, Inc. | Compositions et procedes pour la modulation de la pharmacocinetique et de la pharmacodynamie de l'insuline |
BR112013032396A2 (pt) | 2011-06-17 | 2016-11-22 | Halozyme Inc | formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico |
EA201400030A1 (ru) | 2011-06-17 | 2014-07-30 | Галозим, Инк. | Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
US20130231281A1 (en) * | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
RS59703B1 (sr) | 2011-12-30 | 2020-01-31 | Halozyme Inc | Varijante ph20 polipeptida, njihove formulacije i upotrebe |
US9399065B2 (en) * | 2012-04-16 | 2016-07-26 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin |
US9381247B2 (en) | 2012-04-16 | 2016-07-05 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
US20150174209A1 (en) | 2012-05-25 | 2015-06-25 | Amylin Pharmaceuticals. Llc | Insulin-pramlintide compositions and methods for making and using them |
CN104902922B (zh) * | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
US20150065423A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations |
CA2936563A1 (fr) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Formulations d'insuline a action rapide et systemes d'administration pharmaceutique |
WO2015120457A1 (fr) | 2014-02-10 | 2015-08-13 | Biodel Inc. | Formulations d'insuline à action ultrarapide stabilisées |
US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
-
2015
- 2015-12-01 AR ARP150103921A patent/AR102869A1/es unknown
- 2015-12-01 TW TW104140209A patent/TW201630622A/zh unknown
- 2015-12-09 MD MDE20170200T patent/MD3233108T2/ro unknown
- 2015-12-09 SI SI201531823T patent/SI3233108T1/sl unknown
- 2015-12-09 DK DK15817678.4T patent/DK3233108T3/da active
- 2015-12-09 ES ES15817678T patent/ES2911207T3/es active Active
- 2015-12-09 EP EP22164140.0A patent/EP4108253A1/fr active Pending
- 2015-12-09 MA MA41188A patent/MA41188B1/fr unknown
- 2015-12-09 US US14/963,279 patent/US9993555B2/en active Active
- 2015-12-09 PT PT158176784T patent/PT3233108T/pt unknown
- 2015-12-09 HU HUE15817678A patent/HUE058764T2/hu unknown
- 2015-12-09 WO PCT/US2015/064744 patent/WO2016100042A1/fr active Application Filing
- 2015-12-09 PL PL15817678T patent/PL3233108T3/pl unknown
- 2015-12-09 LT LTEPPCT/US2015/064744T patent/LT3233108T/lt unknown
- 2015-12-09 RS RS20220416A patent/RS63174B1/sr unknown
- 2015-12-09 HR HRP20220692TT patent/HRP20220692T1/hr unknown
- 2015-12-09 JP JP2017531725A patent/JP6328855B2/ja active Active
- 2015-12-09 EP EP15817678.4A patent/EP3233108B1/fr active Active
-
2018
- 2018-04-18 JP JP2018079985A patent/JP7093669B2/ja active Active
- 2018-05-14 US US15/978,329 patent/US11123406B2/en active Active
-
2020
- 2020-12-24 JP JP2020214703A patent/JP7159277B2/ja active Active
-
2021
- 2021-09-17 US US17/478,747 patent/US11872266B2/en active Active
-
2022
- 2022-10-12 JP JP2022163910A patent/JP2023011641A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023011641A (ja) | 2023-01-24 |
EP3233108B1 (fr) | 2022-03-30 |
US20160166695A1 (en) | 2016-06-16 |
JP2018500314A (ja) | 2018-01-11 |
MA41188A (fr) | 2017-10-24 |
MD3233108T2 (ro) | 2022-09-30 |
US9993555B2 (en) | 2018-06-12 |
DK3233108T3 (da) | 2022-04-11 |
JP6328855B2 (ja) | 2018-05-23 |
JP2021073187A (ja) | 2021-05-13 |
HUE058764T2 (hu) | 2022-09-28 |
PT3233108T (pt) | 2022-05-05 |
EP4108253A1 (fr) | 2022-12-28 |
RS63174B1 (sr) | 2022-05-31 |
US11872266B2 (en) | 2024-01-16 |
WO2016100042A1 (fr) | 2016-06-23 |
US20190231851A1 (en) | 2019-08-01 |
US20220072105A1 (en) | 2022-03-10 |
JP2018138578A (ja) | 2018-09-06 |
HRP20220692T1 (hr) | 2022-07-08 |
TW201630622A (zh) | 2016-09-01 |
JP7093669B2 (ja) | 2022-06-30 |
LT3233108T (lt) | 2022-05-10 |
US11123406B2 (en) | 2021-09-21 |
JP7159277B2 (ja) | 2022-10-24 |
AR102869A1 (es) | 2017-03-29 |
EP3233108A1 (fr) | 2017-10-25 |
PL3233108T3 (pl) | 2022-06-20 |
SI3233108T1 (sl) | 2022-05-31 |
ES2911207T3 (es) | 2022-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41188B1 (fr) | Compositions d'insuline à action rapide | |
MA42701B1 (fr) | Compositions d'insuline à action rapide | |
MA39441A1 (fr) | Composition d'insuline a action rapide | |
BR112017024684A2 (pt) | compostos coagonistas de glucagon e glp-1 | |
MA40466A (fr) | Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique | |
PH12017502181A1 (en) | Nutritional compositions containing an elevated level of inositol and uses thereof | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
MA38646A1 (fr) | Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa. | |
MX2017004662A (es) | Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad. | |
MX2017006747A (es) | Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis. | |
MX2016002714A (es) | Composicion y metodo para tropicalizar chocolate. | |
TH1801001060A (th) | องค์ประกอบอินซูลินชนิดออกฤทธิ์รวดเร็ว | |
TH168567A (th) | องค์ประกอบอินซูลินออกฤทธิ์รวดเร็ว | |
MY186341A (en) | Nutritional compositions containing an elevated level of inositol and uses thereof | |
AR099750A1 (es) | COMPOSICIONES PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE PATOLOGÍAS RELACIONADAS CON LA a-GLUCOSIDASA |